AstraZeneca Acquires Vaccine Startup; FDA Issues GLP-1 Treatment Warning
AZN Astrazeneca plc
$186.76 -1.39%
View chart & analysis → 
- 1AstraZeneca has acquired Omnios, a vaccine development partner.
- 2The US Food and Drug Administration has requested updates to GLP-1 treatment prescription information to include the risk of a rare disease that can cause vision loss.
- 3Omnios claimed its technology can produce higher quality conjugate vaccines.
So what's the key point?
AstraZeneca has purchased a new company that makes vaccines. This allows for the production of higher quality vaccines using Omnios's technology.
Source BioPharma Dive · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.